A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Eligible for screening study DCP 001
BN011 is closed to accrual, effective February 12, 2026.
